Search for content, post, videos

IRLAB changes CEO and appoints new Chairman

IRLAB Therapeutics has announced that its CEO Richard Godfrey is leaving his position and that the Board of directors has appointed Gunnar Olsson as Interim CEO. This news follows the disappointing Phase IIb trial results of mesdopetam in people with Parkinson's disease levodopa-induced dyskinesi
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.